Absolutely thrilled and over the moon to have matched at Brigham and Women’s for Cardiology!🫀I am deeply grateful for all the help and opportunities I have received at @UTSWInternalMed

From EHR defaults to AI-driven personalization, we outline how nudges can improve guideline use, preventive care, and patient engagement at scale.

Excited to share our paper: “Nudges in a Learning Health System: Applications to Cardiovascular–Kidney–Metabolic Care.” @JACCJournals A deep dive into how behavioral science can enhance CKM care @CassSunstein @ankeetbhatt, @mvaduganathan @hfcollaboratory https://t.co/x5ZZttNYof

Welcome!

Now in press in @CircHF from the Heart Failure Collaboratory (HFC), in simultaneous publication with #AHA25 — Backbone of Trials in a Challenging Environment is out! @mfiuzat @Adriverar @DrNancySweitzer @coconnormd Michael R. Bristow 💙👏 Read more https://t.co/giC7OB4TR0

This is impressive CV risk reduction with Tirzepatide vs Semaglutide The fact that we have these incretin therapies available is a game changer. Now we just have to make them accessible and cheaper #GLP1RA #weightloss #CVRisk #CVPrev #cardiotwitter

Thrilled to share our paper in @JACCJournals @ankeetbhatt @mvaduganathan @hfcollaboratory 🫀This work proposes a standardized Cardiovascular-Kidney-Metabolic Medical Therapy Optimization Score to enhance the capture of background data collection across CKM in trials

Endlessly proud of our #HFC member @Deoliveiragdc 👏🏻👏🏻

Excited to share our editorial in @JAMACardio with Dr. Peter Libby! 🚩🩸 We discuss ASPREE-CHIP data showing ↑🩸risk in older adults w/ CHIP taking ASA. Excited to work w/ Dr. Libby as his CHIP fellow in @BrighamWomens CHIP Clinic these next 2 years! 🔗 https://t.co/QTwi9AJya3

The physical exam changes & evolves but always remains critical to the clinical assessment of a patient. Check out our novel #POCUS protocol to assess volume status #jacchf @JACCJournals 👀 https://t.co/uujYGEuO8p

📍 Accurate, noninvasive RAP estimation is essential in heart failure management 📍 This IJV–CA protocol is intuitive, quick, and requires only basic ultrasound skills 📍 Could help expand hemodynamic assessment #HeartFailure #POCUS

✅ RAP increased stepwise across stages ✅ The protocol showed strong discrimination for elevated RAP (C-statistic = 0.785) ✅ Stages 3–4 had 85% PPV for RAP ≥ 10 mm Hg ✅ Performed successfully even by trainees with limited ultrasound experience #POCUS #Cardiology

We developed a simple 4-stage POCUS classification comparing the IJV to the carotid artery at different positions: no need for distance measurements from the right atrium. 👉 Each higher stage corresponded to higher invasively measured RAP. #EchoFirst #MedTwitter

Thrilled to share our paper in @JACCJournals I had the honor of working with @MarkDrazner @JTThibs and our amazing team on a Novel, bedside 4-stage POCUS protocol to estimate RAP using internal jugular vein–carotid artery comparisons @HFSA

Outstanding presentation and an equally excellent panel discussion led by @vbluml on cardiogenic shock trials at the Inova CV Symposium 2025 💙 #HeartFailure #CardiogenicShock @ISHVnews @mfiuzat @Adriverar @coconnormd

The recent @HFSA/@ASPCardio joint statement on #HeartFailure prevention marks a historic turning point for the field. In the latest #SpecialReport, Dr. Januzzi, @DrMarthaGulati, and @dranulala break down the statement and what it means for the field: https://t.co/lY1D928Vab

Lifetime benefits of combination therapy in HFpEF: actuarial analysis of DELIVER, FINEARTS-HF and PARAGON-HF: - 3.6 years of additional event-free survival with SGLT2i + MRA - 4.9 years of additional event-free survival with SGLT2i + MRA + ARNI Don’t delay 💊 implementation!

Today at #ESCcongress: #HFC member Dr. Ankeet Bhatt presents the breakthrough results of the KP-VACCINATE Megatrial — a landmark study in vaccination and cardiovascular prevention. Congratulations @ankeetbhatt 👏🏼👏🏼 #ESC2025 #WCCardio

📢 Late-breaking #ClinicalScience at #ESCCongress: CONFIDENCE trial (presented by our #HFC member @mvaduganathan shows: Finerenone + Empagliflozin = ✅ Rapid albuminuria reduction ✅ Consistent safety ✅ Benefits across KDIGO risk in #T2D + #CKD #cardiorenal #ESCCongress2025

Now in Circulation, led by #HFC members @mvaduganathan, @ankeetbhatt , and @scottdsolomon. The NUDGE-CKD Trial tested electronic nudges to patients with chronic kidney disease and their providers, underscoring the need for improved workflow strategies. https://t.co/xi7VgOwq4z

#NudgeCKD out in @CircAHA! With rapid treatment advances across #CKM, urgent need to develop frameworks to evaluate whether #ImpSci strategies are effective (or not) rapidly and at scale. @TorBiering @CTCPR_ leading the way yet again in this 2x2 factorial design. @mvaduganathan